Meet Proteona at the 1st Advanced Therapies Science Meeting in Berlin, Germany
Innovative AI-driven genomic and proteomic analysis platform for improving cell therapy and immuno-oncology
Dr Andreas Schmidt, the CEO of Proteona Pte. Ltd., will attend the 1st Advanced Therapies Science Meeting (1ATSM), taking place in Berlin, Germany, from the 25th to the 26th November 2019.
The 1ATSM meeting is part of the RESTORE initiative in Europe. RESTORE aims to accelerate the development of advanced therapies, such as cell and gene therapy, and their translation into clinical standard-of-care. Proteona is a supporter of RESTORE.
For media queries, please contact:
Dr Andreas Schmidt
Proteona is a precision medicine company in Singapore, Germany, and the US that is pioneering the use of single cell multi-omics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona enables pharmaceutical companies, biotech partners, and clinicians to integrate single cell level precision into their clinical projects. Proteona continues to develop comprehensive, disease-specific single cell databases combining gene expression, protein expression, and mutation information derived from each individual cells as well as drug response data for each sample. Proteona has been selected as a “One to Watch” by Nature Research Spinoff Award and a Winner of Falling Walls Ventures Breakthrough of the Year 2020. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR).